Why Is Climb Bio Stock Gaining Friday? - Climb Bio (NASDAQ:CLYM)

Climb Bio (CLYM) shares positive Phase 1b data for budoprutug in ITP, showing robust B-cell depletion and strong platelet responses.

Raccontata dabenzinga.com